The outlook is BRIGHT for Fabry disease
Protalix and Chiesi share encouraging data from Phase 3 trial evaluating pegunigalsidase alfa in Fabry disease
Fabry disease
Advances in Fabry disease
Amicus’ engineered hGLA showed greater substrate reduction than wildtype hGLA
BRIDGE-ing the gap to a new treatment
PRX-102 concludes Phase 3 trial in Fabry disease, improves renal function
Latest Issue
• Volume 17 • Issue 12 • December 2021/January 2022
December 2021/January 2022
December 2021/January 2022 Issue